FY2026 EPS Estimates for Roche Reduced by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Erste Group Bank lowered their FY2026 EPS estimates for shares of Roche in a report issued on Monday, July 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.10 for the year, down from their previous forecast of $3.14. The consensus estimate for Roche’s current full-year earnings is $3.08 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.36 EPS.

RHHBY has been the topic of a number of other research reports. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 target price on the stock in a research report on Friday, April 24th. Zacks Research cut Roche from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Argus raised Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Finally, HSBC lowered Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roche has an average rating of “Hold” and a consensus target price of $51.50.

Roche Stock Up 0.5%

Shares of OTCMKTS RHHBY opened at $55.27 on Friday. The company has a 50-day simple moving average of $51.76 and a 200-day simple moving average of $52.79. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. Roche has a 12 month low of $37.51 and a 12 month high of $60.85.

Institutional Investors Weigh In On Roche

A number of institutional investors have recently bought and sold shares of the stock. McIlrath & Eck LLC acquired a new position in Roche during the first quarter worth approximately $39,000. Oakworth Capital Inc. boosted its holdings in shares of Roche by 20.8% in the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after purchasing an additional 285 shares during the last quarter. Atlas Capital Advisors Inc. acquired a new position in shares of Roche in the 4th quarter valued at $192,000. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in shares of Roche during the 1st quarter valued at $208,000. Finally, Sarver Vrooman Wealth Advisors acquired a new stake in shares of Roche during the 4th quarter worth $287,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.